In a randomized study, we observed a higher incidence of biopsy-proven acute rejection with preemptive valganciclovir therapy as compared with valacyclovir prophylaxis for prevention of cytomegalovirus (CMV) disease after renal transplantation (RTx). Persistence of the virus within the allograft could stimulate the alloimmune response. The aim of our study was to evaluate intragraft CMV infection in patients randomized to the trial.
Methods
RTx recipients at risk of CMV were randomized to pre-emptive therapy with valganciclovir (n=36) for significant CMV viraemia (≥2,000 copies/ml by quantitative PCR in whole blood samples) or 3-month prophylaxis with valacyclovir (n=34). Renal biopsies performed during 12 months post-RTx were analysed for the presence of CMV by real-time PCR and immunohistochemical staining.
Results
A total of 35 patients (59 biopsies) in the pre-emptive group and 31 patients (57 biopsies) with valacyclovir prophylaxis had ≥1 biopsy specimen with sufficient material for intragraft CMV determination. Cumulative incidence of intragraft CMV infection was 14% and 7% (P=0.315) with pre-emptive therapy and prophylaxis, respectively. Patients at risk for primary CMV infection (CMV serological donor-positive and recipient-negative) were at higher risk for intragraft CMV infection (40% versus 5%; P=0.008). CMV viraemia at the time of biopsy was associated with the presence of CMV within the allograft (P<0.001).
Conclusions
During the first year after RTx, the incidence of intragraft CMV infection was relatively low with comparable rates in patients managed by pre-emptive valganciclovir therapy and valacyclovir prophylaxis.
References
1.
FishmanJ.A.Infection in solid-organ transplant recipients.N Engl J Med2007; 357: 2601–2614.
2.
KalilA.C., LevitskyJ., LydenE., StonerJ., FreifeldA.G.Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.Ann Intern Med2005; 143: 870–880.
3.
HodsonE.M., JonesC.A., WebsterA.C.Antiviral medication to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systemic review of randomised controlled trials.Lancet2005; 365: 2105–2115.
4.
SagedalS., HartmannA., NordalK.P.Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.Kidney Int2004; 66: 329–337.
5.
SagedalS., NordalK.P., HartmannA.The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients.Am J Transplant2002; 2: 850–856.
6.
ReischigT., JindraP., SvecovaM., KormundaS., OpatrnyK.Jr., TreskaV.The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.J Clin Virol2006; 36: 146–151.
7.
ReischigT., JindraP., HesO., BoudaM., KormundaS., TreskaV.Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.Transplantation2009; 87: 436–444.
GernaG., LilleriD., FornaraC.Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation.Am J Transplant2006; 6: 2356–2364.
10.
MattesF.M., VargasA., KopycinskiJ.Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation.Am J Transplant2008; 8: 990–999.
11.
KumarD., ChernenkoS., MoussaG.Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.Am J Transplant2009; 9: 1214–1222.
12.
NickelP., BoldG., PresberF.High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.Transpl Immunol2009; 20: 238–242.
BrennanD.C., GarlockK.A., SingerG.G.Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients.Transplantation1997; 64: 1843–1846.
15.
PayaC., HumarA., DominguezE.Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.Am J Transplant2004; 4: 611–620.
16.
LowanceD., NeumayerH.H., LegendreC.M.Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation.N Engl J Med1999; 340: 1462–1470.
17.
ReischigT., JindraP., MaresJ.Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.Transplantation2005; 79: 317–324.
18.
KhouryJ.A., StorchG.A., BohlD.L.Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.Am J Transplant2006; 6: 2134–2143.
19.
ReischigT., JindraP., HesO., SvecovaM., KlabochJ., TreskaV.Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.Am J Transplant2008; 8: 69–77.
20.
KliemV., FrickeL., WollbrinkT., BurgM., RadermacherJ., RohdeF.Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.Am J Transplant2008; 8: 975–983.
21.
KalpoeJ.S., SchippersE.F., ElingY., SijpkensY.W., de FijterJ.W., KroesA.C.M.Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.Antivir Ther2005; 10: 119–123.
22.
HelanteräI., KoskinenP., TörnrothT., LoginovR., Grönhagen-RiskaC., LautenschlagerI.The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients.Transplantation2003; 75: 1858–1864.
23.
HelanteräI., KoskinenP., FinneP.Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival.Transpl Int2006; 19: 893–900.
24.
SolezK., ColvinR.B., RacusenL.C.el al. Banff ‘05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN’).Am J Transplant2007; 7: 518–526.
25.
van DongenJ.J., LangerakA.W., BrüggemannM.Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.Leukemia2003; 17: 2257–2317.
KlooverJ.S., SootsA.P., KrogerusL.A.Tar cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft.Transplantation2000; 69: 2641–2647.
28.
GuliziaJ.M., KandolfR., KendallT.J.Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts.Am J Pathol1995; 147: 461–475.
29.
WelshR.M., SelinL.K.No one is naive: The significance of heterologous T-cell immunity.Nat Rev Immunol2002; 2: 417–426.
30.
ReinkeP., ProschS., KernF., VolkH.D.Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients.Transpl Infect Dis1999; 1: 157–164.
31.
van DorpW.T., JongesE., BruggemanC.A.Direct induction of MHC class I, but not class II, expression on endothelial cells by cytomegalovirus infection.Transplantation1989; 48: 469–472.
32.
StassenF.R., Vega-CordovaX., VliegenI., BruggemanC.A.Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease?J Clin Virol2006; 35: 349–353.
33.
LiapisH., StorchG.A., HillD.A., RuedaJ., BrennanD.C.CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue PCR.Nephrol Dial Transplant2003; 18: 397–402.
34.
ChemalyR.F., Yen-LiebermanB., ChapmanJ.Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients.Am J Transplant2005; 5: 544–548.
